Get started
Author

Sujith Dhanasiri

Paying the price: the cost of mental health care in England to 2026
2008 · Paul McCrone, Sujith Dhanasiri, et al. · Research Portal (King's College London) · 437
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
2020 · Murielle Roussel, Benjamin Hebraud, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 41
Economic impact of services for first‐episode psychosis: a decision model approach
2009 · Paul McCrone, Martin Knapp, et al. · Early Intervention in Psychiatry · 39
Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis
2016 · Sue Harnan, Shiji Ren, et al. · Acta Haematologica · 36
PDF
Dementia UK : a report into the prevalence and cost of dementia.
2007 · Martín Knapp, Prince Miles, et al. · Europe PMC (PubMed Central) · 36
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales
2012 · Ruth E. Brown, Sean Stern, et al. · The European Journal of Health Economics · 31
Transition pathways for young people with complex disabilities: exploring the economic consequences
2008 · M. Knapp, M. Perkins, et al. · Child Care Health and Development · 29
PDF
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM ‐003 trial for pomalidomide plus low‐dose dexamethasone
2014 · Gareth Morgan, Antonio Palumbo, et al. · British Journal of Haematology · 24
PDF
Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study
2021 · Sujith Dhanasiri, Georgia Hollier-Hann, et al. · Clinical Therapeutics · 22
Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy
2019 · Graham Jackson, Jayne Galinsky, et al. · European Journal Of Haematology · 21
PDF
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma
2021 · Paula Rodriguez-Otero, Dieter Ayers, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 20
Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma
2022 · Nina Shah, Ali Mojebi, et al. · Journal of Comparative Effectiveness Research · 18
Paying the Price
2008 · Paul McCrone, Sujith Dhanasiri, et al. · 15
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
2020 · Katja Weisel, Meletios Dimopoulos, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 13
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody
2024 · Karthik Ramasamy, Ravi Vij, et al. · Clinical Lymphoma Myeloma & Leukemia · 12
Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment
2020 · Carin A. Uyl‐de Groot, Rachel Ramsden, et al. · European Journal Of Haematology · 11
PDF
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis
2019 · Karthik Ramasamy, Sujith Dhanasiri, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 11
PDF
Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales
2018 · Jason Tay, Ravi Vij, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 10
Chart Review Across EU5 in MM Post-ASCT Patients
2018 · John Ashcroft, Davneet Judge, et al. · International Journal of Hematologic Oncology · 10
PDF
An Evaluation of the Use of Electronic Monitoring as a Condition of Bail in Scotland
2007 · Barry, Monica, Malloch, Margaret, et al. · Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) · 9
PDF
Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens
2021 · Elena Zamagni, Sujith Dhanasiri, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 8
PDF
Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial
2020 · Michel Delforge, Nina Shah, et al. · Blood · 8
Lenalidomide As Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation: A Pharmacoeconomic Assessment in the Netherlands
2018 · Carin A. Uyl-de Groot, Rachel Ramsden, et al. · Blood · 7
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
2023 · Albert Oriol, Meletios Dimopoulos, et al. · Clinical Lymphoma Myeloma & Leukemia · 6
PDF
A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure
2023 · Faith E. Davies, Xavier Leleu, et al. · Clinical Lymphoma Myeloma & Leukemia · 6
PDF
Works count: 78
Citation count: 934
H-index: 13
I10-index: 19
Year
Topic
Type